Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Короткий путь к заветной цели – ко-ренитек для пациента с АГ
Короткий путь к заветной цели – ко-ренитек для пациента с АГ
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Collins R, Peto R. Antihypertensive drug therapy: effects on stroke and coronary heart disease. In: Swales JD, ed. Textbook of Hypertension. Oxford: Blackwell Publications. 1994; 1156–64.
2. Moser M, Herbert P, Hennekens CR. An overview of the metaanalysis of the hypertension treatment trials. Arch Intern Med 1991; 151: 1277–9.
3. Lewington S et al. Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360 (9349): 1903–13.
4. Vasan RS, Larson MG et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345 (18): 1291–7.
5. 1999 World Health Organization – International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151–83.
6. 2003 European Society of Hypertension – European Society of Cardiology Guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53.
7. Chobanian AV, Bakris GL, Blorck HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA 2003; 289: 2560–72.
8. Рекомендации по профилактике, диагностике и лечению артериальной гипертензии. Российские рекомендации (второй пересмотр). Комитет экспертов Всероссийского научного общества кардиологов. Секция артериальной гипертонии ВНОК. М., 2004. Приложение к журн. "Кардиоваскул. тер. и профилак.".
9. Blood pressure lowering treatment trialists' collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527–35.
10. Brown CL, Backhouse CI, Grippat JC, Santoni JP. The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects. Eur J Clin Pharmacol 1990; 39: 327–32.
11. Muiesan G, Agabiti-Rosei E, Buoninconti R. Antihypertensive efficacy and tolerability of captopril in elderly: comparison with hydrochlorothiazide and placebo in a multicentre double-blind study. J Hypertens 1987; 2: 89–92.
12. Sassano P, ChatellierG, Billaud E et al. Comparison of increase in the enalapril dose and addition of hydrochlorothizide as second-step treatment of hypertensive patients not controlled by enalapril alone. J Cardiovasc Pharmacol 1989; 13: 314–9.
13. Weinberger MH. Comparison of captopril and hydrochlorothi-azide alone and in combination in mild to moderate essential hypertension. Br J Clin Pharmacol 1982; 14: 127–31.
14. Zanchetti A, Desche P. Perindopril. First-line treatment for hypertension. Clin Exp Ther Pract 1989; All: 555–73.
15. Scholze J, Group for the East Germany Collaborative Trial. Short report: ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design. J Hypertens 1993; 11: 217–21.
2. Moser M, Herbert P, Hennekens CR. An overview of the metaanalysis of the hypertension treatment trials. Arch Intern Med 1991; 151: 1277–9.
3. Lewington S et al. Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360 (9349): 1903–13.
4. Vasan RS, Larson MG et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345 (18): 1291–7.
5. 1999 World Health Organization – International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151–83.
6. 2003 European Society of Hypertension – European Society of Cardiology Guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53.
7. Chobanian AV, Bakris GL, Blorck HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA 2003; 289: 2560–72.
8. Рекомендации по профилактике, диагностике и лечению артериальной гипертензии. Российские рекомендации (второй пересмотр). Комитет экспертов Всероссийского научного общества кардиологов. Секция артериальной гипертонии ВНОК. М., 2004. Приложение к журн. "Кардиоваскул. тер. и профилак.".
9. Blood pressure lowering treatment trialists' collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527–35.
10. Brown CL, Backhouse CI, Grippat JC, Santoni JP. The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects. Eur J Clin Pharmacol 1990; 39: 327–32.
11. Muiesan G, Agabiti-Rosei E, Buoninconti R. Antihypertensive efficacy and tolerability of captopril in elderly: comparison with hydrochlorothiazide and placebo in a multicentre double-blind study. J Hypertens 1987; 2: 89–92.
12. Sassano P, ChatellierG, Billaud E et al. Comparison of increase in the enalapril dose and addition of hydrochlorothizide as second-step treatment of hypertensive patients not controlled by enalapril alone. J Cardiovasc Pharmacol 1989; 13: 314–9.
13. Weinberger MH. Comparison of captopril and hydrochlorothi-azide alone and in combination in mild to moderate essential hypertension. Br J Clin Pharmacol 1982; 14: 127–31.
14. Zanchetti A, Desche P. Perindopril. First-line treatment for hypertension. Clin Exp Ther Pract 1989; All: 555–73.
15. Scholze J, Group for the East Germany Collaborative Trial. Short report: ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design. J Hypertens 1993; 11: 217–21.
Авторы
И.Е.Чазова, Л.Г.Ратова
Отдел системных гипертензий (рук. – д.м.н. И.Е.Чазова) Института клинической кардиологии
им. А.Л.Мясникова (директор – акад. РАМН, член-корр. РАН Ю.Н.Беленков), Российский кардиологический научно-производственный комплекс (генеральный директор – академик РАН Е.И.Чазов) МЗ и СР РФ
Отдел системных гипертензий (рук. – д.м.н. И.Е.Чазова) Института клинической кардиологии
им. А.Л.Мясникова (директор – акад. РАМН, член-корр. РАН Ю.Н.Беленков), Российский кардиологический научно-производственный комплекс (генеральный директор – академик РАН Е.И.Чазов) МЗ и СР РФ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.